fep blue glp 1 coverage 2026 Upcoming Insurance Changes for GLP-1 Medications: What You Need to Know Medicare Bridge Program Explained: GLP-1

LEAP-2 (Liver-expressed antimicrobial peptide 2) has been characterized as an endogenous competitive antagonist of ghrelin and proposed as a potential therapeutic target for obesity (128, 129)

Autoimmune considerations : There is no evidence that GLP-1 receptor agonists worsen autoimmune thyroid disease or trigger new-onset Hashimoto's thyroiditis

It can significantly reduce body weight while also improving glycemic control, making it a beneficial option for managing obesity in this population

Additionally, some patients report improved quality of life related to better glucose control, weight loss, and the convenience of once-weekly dosing options

Two stars